RxDoctor Payments Data

Eduardo Enriquez, MD

Internal Medicine · Voorhees, NJNPI 1063573616

Payments from drug & device makers

$604in general payments, 2019–2025

Across 19 payments — averaging $31.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$273
  • Johnson & Johnson$92
  • Lilly USA, LLC$33
  • Novartis$32
  • Amgen$31
  • Sunovion Pharmaceuticals Inc.$22
  • plus $121 from 7 others

What the payments were for

  • Food & beverage$604100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$604 in reported general payments places this provider in the 55th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$124,486
Medicare patients
263
Services billed
1,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$81,361
OzempicSemaglutide44$60,370
BiktarvyBictegrav/Emtricit/Tenofov Ala11$46,709
XareltoRivaroxaban118$37,094
FarxigaDapagliflozin Propanediol46$35,744
JanuviaSitagliptin Phosphate54$32,057
MounjaroTirzepatide17$31,300
JardianceEmpagliflozin38$24,137
Xtampza ErOxycodone Myristate13$15,388
InvokanaCanagliflozin16$14,166
Tresiba Flextouch U-100Insulin Degludec11$10,400
MyrbetriqMirabegron27$9,753
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$8,152
Atorvastatin Calcium740$7,812
Gabapentin251$7,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$17$60,37044 claims
Johnson & JohnsonXarelto, Invokana$92$51,260134 claims
Lilly USA, LLCMounjaro$33$31,30017 claims
GSKTrelegy Ellipta$19$8,15215 claims
NovartisEntresto$32$6,23516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Voorhees

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →